The association between hepatitis C virus (HCV) infection and chronic kidney disease (CKD) is well established and remains an area of intense research. HCV infection is associated with a large spectrum of histo-patholog-ical lesions in both native and transplanted kidneys. The frequency of kidney damage in HCV-infected patients appears low even if is not fully detailed. The most frequent HCV-associated renal lesion is type I membrano proliferative glomerulonephritis, usually in the context of type II mixed cryoglobuline mia. Various approaches have been tried for the treatment of HCV-related glomerulone phritis, including immunosuppressive ther apy (corticosteroids and cytotoxic agents), plasma exchange and antiviral agents. Anti viral treatment of HCV-associated glomeru lonephritis has shown encouraging results. Immunosuppressive therapy is particularly recommended for cryoglobulinemic kidney disease. Two distinct approaches should be considered for the treatment of HCV-asso ciated cryoglobulinemic glomerulonephri tis according to the level of proteinuria and kidney failure. Some evidence on rituximab therapy for HCV-related cryoglobulinemic glomerulonephritis exists but several ques tions related to its use need to be addressed.
|Number of pages||11|
|Journal||Minerva Urologica e Nefrologica|
|Publication status||Published - Jun 1 2014|
- Hepatitis C, chronic
- Kidney failure, chronic
- Liver diseases
ASJC Scopus subject areas